<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9092</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9092</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">AAN&apos;s First 21st-Century Position Statement on Ethical Consideration in Dementia Diagnosis and Care</style></title><secondary-title><style face="normal" font="default" size="100%">Neurology</style></secondary-title><short-title><style face="normal" font="default" size="100%">AAN&apos;s First 21st-Century Position Statement on Ethical Consideration in Dementia Diagnosis and Care</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurology</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Neurology</style></abbr-2></periodical><pages><style face="normal" font="default" size="100%">704-704</style></pages><volume><style face="normal" font="default" size="100%">97</style></volume><number><style face="normal" font="default" size="100%">14</style></number><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">0028-3878</style></isbn><abstract><style face="normal" font="default" size="100%">The Editor retracts this editorial1 at the request of the author because the author&apos;s views on the topic are no longer reflected in the editorial in light of the FDA&apos;s approval of the drug aducanumab for use in treatment of Alzheimer disease. The FDA approved the drug on June 7, 2021, after the editorial was submitted (February 25, 2021) or accepted in final form by Neurology (March 4, 2021) but before it was published (July 13, 2021).</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">corrected article. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 0401060. PMID: NLM34520387.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://search.ebscohost.com/login.aspx?direct=true&amp;db=cin20&amp;AN=152770499&amp;site=ehost-live</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1212/WNL.0000000000012606</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">cin20</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">EBSCOhost</style></remote-database-provider></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9104</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9104</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Ethical Controversy Erupts Over Alzheimer&apos;s Drug Approval</style></title><secondary-title><style face="normal" font="default" size="100%">Medical Ethics Advisor</style></secondary-title><short-title><style face="normal" font="default" size="100%">Ethical Controversy Erupts Over Alzheimer&apos;s Drug Approval</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medical Ethics Advisor</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-4</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer&apos;s Disease -- Drug Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Approval -- Ethical Issues</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal -- Therapeutic Use</style></keyword><keyword><style face="normal" font="default" size="100%">United States Food and Drug Administration</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal -- Adverse Effects</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcomes</style></keyword><keyword><style face="normal" font="default" size="100%">Mild Cognitive Impairment -- Drug Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal -- Economics</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Markers -- Ethical Issues</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">0886-0653</style></isbn><abstract><style face="normal" font="default" size="100%">The first new Alzheimer&apos;s drug to be approved in almost 20 years has sparked a major ethical controversy, leading to protest resignations, criticism, qualifying statements, and even calls for investigations.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">USA. NLM UID: 8511817.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://search.ebscohost.com/login.aspx?direct=true&amp;db=cin20&amp;AN=151683024&amp;site=ehost-live</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">cin20</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">EBSCOhost</style></remote-database-provider></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9114</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anderson, Timothy S.</style></author><author><style face="normal" font="default" size="100%">Ayanian, John Z.</style></author><author><style face="normal" font="default" size="100%">Souza, Jeffrey</style></author><author><style face="normal" font="default" size="100%">Landon, Bruce E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor Editor, JAMA Health Forum Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="default" size="100%">Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA: Journal of the American Medical Association</style></secondary-title><short-title><style face="normal" font="default" size="100%">Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA: Journal of the American Medical Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1627-1629</style></pages><volume><style face="normal" font="default" size="100%">326</style></volume><number><style face="normal" font="default" size="100%">16</style></number><keywords><keyword><style face="normal" font="default" size="100%">Medicare -- Statistics and Numerical Data</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer&apos;s Disease -- Drug Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal -- Therapeutic Use</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal -- Adverse Effects</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Age</style></keyword><keyword><style face="normal" font="default" size="100%">United States Food and Drug Administration</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Approval</style></keyword><keyword><style face="normal" font="default" size="100%">Insurance -- Statistics and Numerical Data</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Selection</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and Over</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">0098-7484</style></isbn><abstract><style face="normal" font="default" size="100%">This study evaluates whether patients enrolled in trials of aducanumab, EMERGE and ENGAGE, were representative of patients with dementia enrolled in Medicare by estimating the proportions of Medicare beneficiaries with Alzheimer disease (AD) or mild cognitive impairment (MCI) who would have been excluded from these trials.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">letter; research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: P01 AG032952/AG/NIA NIH HHS/United States. NLM UID: 7501160. PMID: NLM34499725.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://search.ebscohost.com/login.aspx?direct=true&amp;db=cin20&amp;AN=153315801&amp;site=ehost-live</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.2021.15286</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">cin20</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">EBSCOhost</style></remote-database-provider></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9108</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Angrist, M.</style></author><author><style face="normal" font="default" size="100%">Yang, A.</style></author><author><style face="normal" font="default" size="100%">Kantor, B.</style></author><author><style face="normal" font="default" size="100%">Chiba-Falek, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Angrist, Misha. Initiative for Science and Society and Social Science Research Institute, Duke University, Durham, North Carolina, 27708-0222, USA. misha.angrist@duke.edu. Yang, Anna. Duke University, Durham, USA. Kantor, Boris. Duke University Department of Neurobiology, Durham, North Carolina, 27710-3209, USA. Chiba-Falek, Ornit. Duke University Department of Neurology, 311 Research Drive, Durham, North Carolina, 27710-2900, USA. Chiba-Falek, Ornit. Duke Center For Genomic And Computational Biology, Durham, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">Life Sciences, Society and Policy</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Life Sci Soc Policy</style></alt-title><short-title><style face="normal" font="default" size="100%">Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer&apos;s disease</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Life Sciences, Society and Policy</style></full-title><abbr-1><style face="normal" font="default" size="100%">Life Sci Soc Policy</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Life Sciences, Society and Policy</style></full-title><abbr-1><style face="normal" font="default" size="100%">Life Sci Soc Policy</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">11</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default" size="100%">Early Diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Policy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Late Onset Disorders/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default" size="100%">*Social Factors</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 12</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2195-7819</style></isbn><accession-num><style face="normal" font="default" size="100%">33043412</style></accession-num><abstract><style face="normal" font="default" size="100%">In the United States alone, the prevalence of AD is expected to more than double from six million people in 2019 to nearly 14 million people in 2050. Meanwhile, the track record for developing treatments for AD has been marked by decades of failure. But recent progress in genetics, neuroscience and gene editing suggest that effective treatments could be on the horizon. The arrival of such treatments would have profound implications for the way we diagnose, triage, study, and allocate resources to Alzheimer&apos;s patients. Because the disease is not rare and because it strikes late in life, the development of therapies that are expensive and efficacious but less than cures, will pose particular challenges to healthcare infrastructure. We have a window of time during which we can begin to anticipate just, equitable and salutary ways to accommodate a disease-modifying therapy Alzheimer&apos;s disease. Here we consider the implications for caregivers, clinicians, researchers, and the US healthcare system of the availability of an expensive, presymptomatic treatment for a common late-onset neurodegenerative disease for which diagnosis can be difficult.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Angrist, Misha Yang, Anna Kantor, Boris Chiba-Falek, Ornit</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1186/s40504-020-00106-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9098</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9098</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beattie, B. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Beattie, B Lynn. Department of Medicine, Division of Geriatric Medicine, University of British Columbia, Vancouver, BC, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Consent in Alzheimer&apos;s disease research: risk/benefit factors</style></title><secondary-title><style face="normal" font="default" size="100%">Canadian Journal of Neurological Sciences</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Can J Neurol Sci</style></alt-title><short-title><style face="normal" font="default" size="100%">Consent in Alzheimer&apos;s disease research: risk/benefit factors</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Canadian Journal of Neurological Sciences</style></full-title><abbr-1><style face="normal" font="default" size="100%">Can. J. Neurol. Sci.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Can J Neurol Sci</style></abbr-2></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Canadian Journal of Neurological Sciences</style></full-title><abbr-1><style face="normal" font="default" size="100%">Can. J. Neurol. Sci.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Can J Neurol Sci</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">S27-31</style></pages><volume><style face="normal" font="default" size="100%">34 Suppl 1</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/px [Psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Canada</style></keyword><keyword><style face="normal" font="default" size="100%">*Clinical Protocols/st [Standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/es [Ethics]</style></keyword><keyword><style face="normal" font="default" size="100%">*Clinical Trials as Topic/st [Standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Informed Consent/lj [Legislation &amp; Jurisprudence]</style></keyword><keyword><style face="normal" font="default" size="100%">Informed Consent/px [Psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">*Informed Consent/st [Standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Competency/px [Psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Competency/st [Standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Nootropic Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Selection/es [Ethics]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment/es [Ethics]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment/st [Standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Withholding Treatment/es [Ethics]</style></keyword><keyword><style face="normal" font="default" size="100%">Withholding Treatment/st [Standards]</style></keyword><keyword><style face="normal" font="default" size="100%">0 (Nootropic Agents)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0317-1671</style></isbn><accession-num><style face="normal" font="default" size="100%">17469678</style></accession-num><abstract><style face="normal" font="default" size="100%">In the era of chronic disease, we are challenged to find therapies that provide symptomatic relief and ideally, alter the course of the underlying disease. In Alzheimer&apos;s disease (AD), these issues are complicated by the disease itself, which affects the subject&apos;s decision-making capacity for participation in the research. According to established ethical guidelines it is clear that individuals with impaired capacity may participate in research and their risk should be no greater than that which the individual would have in day to day activities with anticipation of benefits within that realm. Decision making processes are complex and involve proxies who themselves have biases about their loved one and the potential for participating in the research. Newer disease-modifying approaches such as immunotherapy have potential for affecting the course of the underlying disease but with greater risk of more significant side effects. Ideally the health care of the subjects is not disadvantaged by research participation. At the same time, trials of potentially riskier therapy are relevant in subjects with the disease. Research for subjects with AD must have appropriate safeguards in place to enable effective progress in innovative therapy for a vulnerable, often elderly population. Recommendations are made which could further our capacity to undertake ethical research in the AD population. [References: 28]</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Beattie, B Lynn</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1017/s0317167100005527</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9094</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9094</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berghmans, R. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Berghmans, R L. Instituut voor Gezondheidsethiek, Universiteit Maastricht. r.berghmans@ige.unimaas.nl</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Anti-Alzheimer drugs: ethical aspects of research and practice]</style></title><secondary-title><style face="normal" font="default" size="100%">Tijdschrift voor Gerontologie en Geriatrie</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Tijdschr Gerontol Geriatr</style></alt-title><short-title><style face="normal" font="default" size="100%">[Anti-Alzheimer drugs: ethical aspects of research and practice]</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Tijdschrift voor Gerontologie en Geriatrie</style></full-title><abbr-1><style face="normal" font="default" size="100%">Tijdschr. Gerontol. Geriatr.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Tijdschr Gerontol Geriatr</style></abbr-2></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Tijdschrift voor Gerontologie en Geriatrie</style></full-title><abbr-1><style face="normal" font="default" size="100%">Tijdschr. Gerontol. Geriatr.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Tijdschr Gerontol Geriatr</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">100-6</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Adaptation, Psychological/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/nu [Nursing]</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/px [Psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Caregivers/px [Psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/mt [Methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/px [Psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Informed Consent</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands</style></keyword><keyword><style face="normal" font="default" size="100%">Nootropic Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">*Nootropic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">0 (Nootropic Agents)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><orig-pub><style face="normal" font="default" size="100%">Anti-Alzheimermiddelen: ethische aspecten van research en praktijk</style></orig-pub><isbn><style face="normal" font="default" size="100%">0167-9228</style></isbn><accession-num><style face="normal" font="default" size="100%">10900662</style></accession-num><abstract><style face="normal" font="default" size="100%">The development and use of drugs that aim at positively influencing the cognitive decline in patients suffering from Alzheimer&apos;s disease raises a number of ethical questions. These concern, amongst others, the significance of these drugs for the well-being and quality of life of patients, as well as the informed consent for the use of these medicines, in particular in the context of medical-scientific research. Assessing the value and significance of antidementia drugs not only depends on the positive effect on cognitive decline, but also on the broader meaning for the quality of life of the patient and her primary carer(s). The subjective experiences of those directly involved deserve more attention in research. [References: 54]</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Berghmans, R L</style></notes><work-type><style face="normal" font="default" size="100%">Case Reports Review</style></work-type><urls></urls><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">Dutch</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9101</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9101</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Daly, T.</style></author><author><style face="normal" font="default" size="100%">Herrup, K.</style></author><author><style face="normal" font="default" size="100%">Espay, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Daly, Timothy. UMR 8011 Sorbonne Universite. Herrup, Karl. University of Pittsburgh School of Medicine. Espay, Alberto J. University of Cincinnati.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer&apos;s Disease</style></title><secondary-title><style face="normal" font="default" size="100%">Ajob Neuroscience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">AJOB Neurosci</style></alt-title><short-title><style face="normal" font="default" size="100%">An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer&apos;s Disease</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">AJOB Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">AJOB Neurosci.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">AJOB Neurosci</style></abbr-2></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">AJOB Neuroscience</style></full-title><abbr-1><style face="normal" font="default" size="100%">AJOB Neurosci.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">AJOB Neurosci</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">80-81</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloid/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloidogenic Proteins/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">0 (Amyloid)</style></keyword><keyword><style face="normal" font="default" size="100%">0 (Amyloidogenic Proteins)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr-Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2150-7759</style></isbn><accession-num><style face="normal" font="default" size="100%">36197130</style></accession-num><abstract><style face="normal" font="default" size="100%">Given the past two decades of over 40 failed trials of amyloid-lowering therapies in Alzheimer&apos;s Disease (AD), many of which succeeded in lowering amyloid as designed, we present an ethical argument for emptying the drug pipeline of tests of amyloid-lowering agents so as to end the historical dominance of the amyloid-reducing therapeutic approach in AD.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Daly, Timothy Herrup, Karl Espay, Alberto J</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1080/21507740.2022.2129858</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9110</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9110</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Daly, T. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Daly, Timothy P. FLACSO Argentina, Buenos Aires, Argentina.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Informing consent to antibodies in Alzheimer&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Bmj</style></alt-title><short-title><style face="normal" font="default" size="100%">Informing consent to antibodies in Alzheimer&apos;s disease</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMJ</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">BMJ</style></abbr-2></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">BMJ</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMJ</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">BMJ</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">2350</style></pages><volume><style face="normal" font="default" size="100%">383</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Informed Consent</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Competency</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">10 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1756-1833</style></isbn><accession-num><style face="normal" font="default" size="100%">37821123</style></accession-num><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Daly, Timothy P Comment on (CON)</style></notes><work-type><style face="normal" font="default" size="100%">Letter Comment</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1136/bmj.p2350</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9112</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9112</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dark, Heather E.</style></author><author><style face="normal" font="default" size="100%">Walker, Keenan A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Behavioral Neuroscience, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA</style></auth-address><titles><title><style face="normal" font="default" size="100%">New IDEAS about amyloid, race and dementia disparities</style></title><secondary-title><style face="normal" font="default" size="100%">Nature Reviews Neurology</style></secondary-title><short-title><style face="normal" font="default" size="100%">New IDEAS about amyloid, race and dementia disparities</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nature Reviews Neurology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5-6</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2023</style></year></dates><isbn><style face="normal" font="default" size="100%">1759-4758</style></isbn><abstract><style face="normal" font="default" size="100%">In a study of 17,000 Medicare beneficiaries with mild cognitive impairment or dementia, non-Hispanic white older adults were more likely than Asian, Black or Hispanic older adults to have elevated cortical amyloid, as measured by PET. These findings have important implications for the use of amyloid-targeting therapies.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Europe; UK &amp; Ireland. NLM UID: 101500072. PMID: NLM36380025.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://search.ebscohost.com/login.aspx?direct=true&amp;db=cin20&amp;AN=161137139&amp;site=ehost-live</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/s41582-022-00748-0</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">cin20</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">EBSCOhost</style></remote-database-provider></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9099</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9099</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gauthier, S.</style></author><author><style face="normal" font="default" size="100%">Leuzy, A.</style></author><author><style face="normal" font="default" size="100%">Racine, E.</style></author><author><style face="normal" font="default" size="100%">Rosa-Neto, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Gauthier, S. McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Quebec, Canada. Electronic address: serge.gauthier@mcgill.ca.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosis and management of Alzheimer&apos;s disease: past, present and future ethical issues</style></title><secondary-title><style face="normal" font="default" size="100%">Progress in Neurobiology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Prog Neurobiol</style></alt-title><short-title><style face="normal" font="default" size="100%">Diagnosis and management of Alzheimer&apos;s disease: past, present and future ethical issues</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Progress in Neurobiology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Prog. Neurobiol.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Prog Neurobiol</style></abbr-2></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Progress in Neurobiology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Prog. Neurobiol.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Prog Neurobiol</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">102-13</style></pages><volume><style face="normal" font="default" size="100%">110</style></volume><keywords><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/es [Ethics]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/hi [History]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/td [Trends]</style></keyword><keyword><style face="normal" font="default" size="100%">*Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Early Diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1873-5118</style></isbn><accession-num><style face="normal" font="default" size="100%">23578568</style></accession-num><abstract><style face="normal" font="default" size="100%">There is great interest in the ethical issues associated with Alzheimer&apos;s disease (AD) and related dementias given the prevalence of AD and the evolving neuroscience landscape in matters of diagnoses and therapeutics. Much of the ethics discussion arises in the tension between the principle of not doing harm (principle of non-maleficence) in this vulnerable population and the development of effective treatments (principle of beneficence). Autonomy and capacity issues are also numerous, wide-ranging, and concern (1) day to day affairs such as driving safely and spending money wisely, (2) life-time events such as designating a legal representative in case of incapacity, making a will, (3) consenting to treatment and diagnostic procedures, (4) participating in research. The latter issue is particularly thorny and illustrates well the complexity of tackling concerns related to capacity. The impetus to protect AD patients has partly led to ethics regulation and policies making research on inapt patients more difficult because of stringent requirements for signed informed consent or for showing the value of the research to this specific patient population. New issues are arising that relate to earlier diagnosis using biomarkers and (possibly soon) the use of drugs that modify disease progression. We here summarize and discuss the different ethical issues associated with AD from a historical perspective, with emphasis on diagnostic and treatments issues.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Gauthier, S Leuzy, A Racine, E Rosa-Neto, P S0301-0082(13)00027-0</style></notes><work-type><style face="normal" font="default" size="100%">Historical Article Review</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1016/j.pneurobio.2013.01.003</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9103</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9103</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gauthier, S.</style></author><author><style face="normal" font="default" size="100%">Rosa-Neto, P.</style></author><author><style face="normal" font="default" size="100%">Kass, J. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients</style></title><secondary-title><style face="normal" font="default" size="100%">CONTINUUM: Lifelong Learning in Neurology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Continuum</style></alt-title><short-title><style face="normal" font="default" size="100%">Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients</style></short-title></titles><alt-periodical><full-title><style face="normal" font="default" size="100%">Continuum</style></full-title><abbr-1><style face="normal" font="default" size="100%">Continuum</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Continuum</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">615-8</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">2 Dementia</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Antipsychotic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/et [Etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default" size="100%">*Ethics, Medical</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">0 (Antipsychotic Agents)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1538-6899</style></isbn><accession-num><style face="normal" font="default" size="100%">27042911</style></accession-num><abstract><style face="normal" font="default" size="100%">This article presents a case in which a patient with mild Alzheimer disease requests a prescription for a newly developed Alzheimer disease drug, after which the patient&apos;s daughter inquires about its potential usefulness as a prevention strategy for herself. The article discusses the physician&apos;s responsibility to balance the ethical principles of beneficence, nonmaleficence, and respect for patient autonomy when evaluating requests for medications from patients with neurocognitive disease as well as from asymptomatic but at-risk patients.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Gauthier, Serge Rosa-Neto, Pedro Kass, Joseph S</style></notes><work-type><style face="normal" font="default" size="100%">Case Reports Research Support, Non-U.S. Gov&apos;t</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1212/CON.0000000000000306</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9107</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9107</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giebel, C.</style></author><author><style face="normal" font="default" size="100%">Cations, M.</style></author><author><style face="normal" font="default" size="100%">Draper, B.</style></author><author><style face="normal" font="default" size="100%">Komuravelli, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Giebel, Clarissa. Institute of Population Health Sciences, University of Liverpool, Liverpool, UK. Giebel, Clarissa. NIHR ARC NWC, Liverpool, UK. Cations, Monica. South Australian Health and Medical Research Institute, Adelaide, Australia. Cations, Monica. College of Medicine and Public Health, Flinders University, Adelaide, Australia. Draper, Brian. School of Psychiatry, University of NSW, Sydney, Australia. Komuravelli, Aravind. North West Boroughs NHS Foundation Trust, Warrington, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ethnic disparities in the uptake of anti-dementia medication in young and late-onset dementia</style></title><secondary-title><style face="normal" font="default" size="100%">International Psychogeriatrics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Int Psychogeriatr</style></alt-title><short-title><style face="normal" font="default" size="100%">Ethnic disparities in the uptake of anti-dementia medication in young and late-onset dementia</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Psychogeriatrics</style></full-title><abbr-1><style face="normal" font="default" size="100%">Int. Psychogeriatr.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Int Psychogeriatr</style></abbr-2></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">International Psychogeriatrics</style></full-title><abbr-1><style face="normal" font="default" size="100%">Int. Psychogeriatr.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Int Psychogeriatr</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">381-390</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Memantine/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholinesterase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Dementia</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Parkinson Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Lewy Body Disease</style></keyword><keyword><style face="normal" font="default" size="100%">W8O17SJF3T (Memantine)</style></keyword><keyword><style face="normal" font="default" size="100%">0 (Cholinesterase Inhibitors)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1741-203X</style></isbn><accession-num><style face="normal" font="default" size="100%">32484120</style></accession-num><abstract><style face="normal" font="default" size="100%">&lt;b&gt;OBJECTIVES&lt;/b&gt;: People with dementia can face barriers when trying to access care after a diagnosis, particularly in young-onset dementia (YOD). Little is known about the effects of ethnicity on the use of anti-dementia medication and variations between age groups. The aim of this study was to analyze national data on variations in the uptake of anti-dementia medication between people with YOD and late-onset dementia (LOD). &lt;b&gt;DESIGN&lt;/b&gt;: Cross-sectional longitudinal cohort study. &lt;b&gt;SETTING&lt;/b&gt;: Data from the U.S. National Alzheimer&apos;s Coordinating Centre were obtained from September 2005 to March 2019. &lt;b&gt;PARTICIPANTS&lt;/b&gt;: First visits of people with a diagnosis of Alzheimer&apos;s disease (AD) dementia, Lewy body dementia (LBD), and Parkinson&apos;s disease dementia (PDD) were included. &lt;b&gt;MEASUREMENTS&lt;/b&gt;: Logistic regression was used to analyze the effects of education and ethnicity on use of cholinesterase inhibitors and memantine, accounting for YOD/LOD, gender, living situation, severity stage, and comorbidities. &lt;b&gt;RESULTS&lt;/b&gt;: In total, 15,742 people with AD dementia and LBD/PDD were included, with 11,019 PwD having completed a first follow-up visit. Significantly more people with YOD used memantine than those with LOD, while fewer used cholinesterase inhibitors. PwD from minority ethnic backgrounds used memantine and cholinesterase inhibitors less often than those from a White ethnic background. Logistic regression analysis showed that ethnicity was a significant determinant of both memantine and cholinesterase inhibitors usage, while education was only a significant determinant for memantine usage. &lt;b&gt;CONCLUSIONS&lt;/b&gt;: Findings highlight the impact of social factors on current usage of anti-dementia medication and the need for more resources to enable equitable use of anti-dementia medication.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Giebel, Clarissa Cations, Monica Draper, Brian Komuravelli, Aravind</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1017/S1041610220000794</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9109</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9109</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giorelli, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Giorelli, Maurizio. Operative Unit of Neurology, Barletta, ASL BT, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inequalities in the Prevention and Treatment of Alzheimer Disease</style></title><secondary-title><style face="normal" font="default" size="100%">Neurology Clinical Practice</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neurol</style></alt-title><short-title><style face="normal" font="default" size="100%">Inequalities in the Prevention and Treatment of Alzheimer Disease</style></short-title></titles><alt-periodical><full-title><style face="normal" font="default" size="100%">Neurology &amp; Therapy</style></full-title><abbr-1><style face="normal" font="default" size="100%">Neurol</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e200283</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2163-0402</style></isbn><accession-num><style face="normal" font="default" size="100%">38720952</style></accession-num><abstract><style face="normal" font="default" size="100%">Incidence of Alzheimer disease (AD) is going to rise in the next years and to become a health and social emergency. The prevention and the therapeutic management of AD still present unmet needs worldwide. The recent approval of monoclonal antibodies against amyloid beta (anti-Abeta mAbs) for AD has increased the level of uncertainty regarding on how such drugs should be administered, to whom, and for how long. Concerns about cost-effectiveness ratios of anti-Abeta mAbs and the need for actual strategies of risk prevention have further dug barriers of inequalities between the national health care systems. Planning research to address questions on the real feasibility of the correct therapeutic management, improving international cooperation on surveillance of risk factors, implementing pathways for timely diagnosis, and effective medical and social support for patients with AD worldwide would be extremely valuable to fight against this upcoming pandemic.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Giorelli, Maurizio</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1212/CPJ.0000000000200283</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9113</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gustavsson, E.</style></author><author><style face="normal" font="default" size="100%">Raaschou, P.</style></author><author><style face="normal" font="default" size="100%">Larfars, G.</style></author><author><style face="normal" font="default" size="100%">Sandman, L.</style></author><author><style face="normal" font="default" size="100%">Juth, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Gustavsson, Erik. Centre for Applied Ethics, Department of Culture and Society, Linkoping University, Linkoping, Sweden erik.gustavsson@liu.se. Gustavsson, Erik. National Centre for Priorities in Health, Department of Health, Medicine and Caring sciences, Linkoping University, Linkoping, Sweden. Raaschou, Pauline. Clinical Pharmacology Unit, Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. Larfars, Gerd. Health and Medical Care Administration, Region Stockholm, Stockholm, Sweden. Sandman, Lars. National Centre for Priorities in Health, Department of Health, Medicine and Caring sciences, Linkoping University, Linkoping, Sweden. Juth, Niklas. Stockholm Centre of Healthcare Ethics, LIME, Karolinska Institute, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Novel drug candidates targeting Alzheimer&apos;s disease: ethical challenges with identifying the relevant patient population</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medical Ethics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J Med Ethics</style></alt-title><short-title><style face="normal" font="default" size="100%">Novel drug candidates targeting Alzheimer&apos;s disease: ethical challenges with identifying the relevant patient population</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Medical Ethics</style></full-title><abbr-1><style face="normal" font="default" size="100%">J. Med. Ethics</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">J Med Ethics</style></abbr-2></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Journal of Medical Ethics</style></full-title><abbr-1><style face="normal" font="default" size="100%">J. Med. Ethics</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">J Med Ethics</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">608-614</style></pages><volume><style face="normal" font="default" size="100%">47</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Brain</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Morals</style></keyword><keyword><style face="normal" font="default" size="100%">*Pharmaceutical Preparations</style></keyword><keyword><style face="normal" font="default" size="100%">0 (Pharmaceutical Preparations)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">09</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1473-4257</style></isbn><accession-num><style face="normal" font="default" size="100%">34117127</style></accession-num><abstract><style face="normal" font="default" size="100%">Intensive research is carried out to develop a disease-modifying drug for Alzheimer&apos;s disease (AD). The development of drug candidates that reduce As or tau in the brain seems particularly promising. However, these drugs target people at risk for AD, who must be identified before they have any, or only moderate, symptoms associated with the disease. There are different strategies that may be used to identify these individuals (eg, population screening, cascade screening, etc). Each of these strategies raises different ethical challenges. In this paper, we analyse these challenges in relation to the risk stratification for AD necessary for using these drugs. We conclude that the new drugs must generate large health benefits for people at risk of developing AD to justify the ethical costs associated with current risk stratification methods, benefits much larger than current drug candidates have. This conclusion raises a new set of ethical questions that should be further discussed.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Gustavsson, Erik Raaschou, Pauline Larfars, Gerd Sandman, Lars Juth, Niklas Comment in (CIN)</style></notes><work-type><style face="normal" font="default" size="100%">Research Support, Non-U.S. Gov&apos;t</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1136/medethics-2021-107304</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9106</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9106</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gustavsson, E.</style></author><author><style face="normal" font="default" size="100%">Raaschou, P.</style></author><author><style face="normal" font="default" size="100%">Larfars, G.</style></author><author><style face="normal" font="default" size="100%">Sandman, L.</style></author><author><style face="normal" font="default" size="100%">Juth, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Gustavsson, Erik. Centre for Applied Ethics, Department of Culture and Society, Linkoping University, Linkoping, Sweden erik.gustavsson@liu.se. Gustavsson, Erik. The National Centre for Priorities in Health, Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden. Raaschou, Pauline. Clinical Pharmacology Unit, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. Larfars, Gerd. Health and Medical Care Administration, Stockholm, Sweden. Sandman, Lars. The National Centre for Priorities in Health, Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden. Juth, Niklas. Stockholm Centre of Healthcare Ethics, LIME, Karolinska Institute, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The ethics of disease-modifying drugs targeting Alzheimer disease: response to our commentators</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medical Ethics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J Med Ethics</style></alt-title><short-title><style face="normal" font="default" size="100%">The ethics of disease-modifying drugs targeting Alzheimer disease: response to our commentators</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Medical Ethics</style></full-title><abbr-1><style face="normal" font="default" size="100%">J. Med. Ethics</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">J Med Ethics</style></abbr-2></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Journal of Medical Ethics</style></full-title><abbr-1><style face="normal" font="default" size="100%">J. Med. Ethics</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">J Med Ethics</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">193</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">03</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1473-4257</style></isbn><accession-num><style face="normal" font="default" size="100%">35115409</style></accession-num><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Gustavsson, Erik Raaschou, Pauline Larfars, Gerd Sandman, Lars Juth, Niklas</style></notes><work-type><style face="normal" font="default" size="100%">Research Support, Non-U.S. Gov&apos;t</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1136/medethics-2022-108157</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9097</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9097</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, T. S.</style></author><author><style face="normal" font="default" size="100%">Gan, C. J. X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Bioethical Issues in Disclosing APOE Genetic Information in Research Programmes</style></title><secondary-title><style face="normal" font="default" size="100%">Asian Bioethics Review</style></secondary-title><short-title><style face="normal" font="default" size="100%">Bioethical Issues in Disclosing APOE Genetic Information in Research Programmes</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Asian Bioethics Review</style></full-title></periodical><pages><style face="normal" font="default" size="100%">85-92</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer&apos;s disease</style></keyword><keyword><style face="normal" font="default" size="100%">Bioethics</style></keyword><keyword><style face="normal" font="default" size="100%">Disclosure</style></keyword><keyword><style face="normal" font="default" size="100%">Ethics</style></keyword><keyword><style face="normal" font="default" size="100%">Genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Health information</style></keyword><keyword><style face="normal" font="default" size="100%">Medical information</style></keyword><keyword><style face="normal" font="default" size="100%">Research</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1793-8759</style></isbn><abstract><style face="normal" font="default" size="100%">Alzheimer&apos;s disease (AD) is the most common type of dementia with a prevalence expected to increase dramatically in coming decades. The only susceptibility gene associated with the most common variant of AD that has been consistently replicated is Apolipoprotein E (APOE). It encodes a protein involved in cholesterol transport. APOE gene exists in three isoforms (e2, e3, e4), differing by single amino acid substitutions, with the e4 allele found to be associated with an increased risk for AD. At present, APOE genotyping is not recommended for clinical purposes but is commonly tested in research protocols. In most research programs, the genotyping result is not disclosed to subjects unless he or she specifically requests for it, unlike other clinically important test results such as incidental tumors on imaging or low serum levels of vitamin B12 and folate. This may change in the future if we gain more knowledge in the pathogenesis of AD and the role of APOE and, disease modifying interventions become available. Nonetheless, at this point, we recommend that a pretest education with the risk information, to be conducted to help research subjects decide on whether to undergo the test itself and whether they would like to know the results now or at a future date.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Using Smart Source Parsing</style></notes><work-type><style face="normal" font="default" size="100%">Journal Article</style></work-type><urls></urls><remote-database-name><style face="normal" font="default" size="100%">PHIL</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9111</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9111</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, N.</style></author><author><style face="normal" font="default" size="100%">Rawal, S.</style></author><author><style face="normal" font="default" size="100%">Young, H. N.</style></author><author><style face="normal" font="default" size="100%">Villa Zapata, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Villa Zapata, Lorenzo. Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, 250 W Green St, RC Wilson Pharmacy, 260H, Athens, GA 30602. Email: Lorenzo.villazapata@uga.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Innovation, affordability, access: Alzheimer disease drugs and the Inflation Reduction Act</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Managed Care</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Am J Manag Care</style></alt-title><short-title><style face="normal" font="default" size="100%">Innovation, affordability, access: Alzheimer disease drugs and the Inflation Reduction Act</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Managed Care</style></full-title><abbr-1><style face="normal" font="default" size="100%">Am. J. Manag. Care</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Am J Manag Care</style></abbr-2></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">American Journal of Managed Care</style></full-title><abbr-1><style face="normal" font="default" size="100%">Am. J. Manag. Care</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Am J Manag Care</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">e169-e171</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/ec [Economics]</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Medicare/ec [Economics]</style></keyword><keyword><style face="normal" font="default" size="100%">*Medicare</style></keyword><keyword><style face="normal" font="default" size="100%">Health Services Accessibility/ec [Economics]</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Services Accessibility</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Costs</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Approval</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1936-2692</style></isbn><accession-num><style face="normal" font="default" size="100%">38912930</style></accession-num><abstract><style face="normal" font="default" size="100%">&lt;b&gt;OBJECTIVES&lt;/b&gt;: This analysis examines the implications of new Alzheimer disease drugs in the era of the Inflation Reduction Act (IRA). It focuses on balancing innovation in Alzheimer disease treatment with affordability and access, assessing the impact on Medicare&apos;s budget, patient cost, and health care system readiness. &lt;b&gt;STUDY DESIGN&lt;/b&gt;: A comprehensive review was conducted, synthesizing information from recent FDA drug approvals, drug pricing models, Medicare coverage policies, and the updated regulations under the IRA. This analysis reflects on the broader clinical and economic consequences of introducing new Alzheimer disease treatments. &lt;b&gt;METHODS&lt;/b&gt;: The study employs a qualitative review of existing literature, policy documents, and economic data. It explores the implications of Alzheimer disease drugs on health care policy, analyzing the economic and clinical impacts within the current health care landscape in the US. &lt;b&gt;RESULTS&lt;/b&gt;: The study highlights the economic challenges posed by the high costs of new Alzheimer disease drugs, contrasting with their moderate clinical benefits and potential risks. It discusses the limitations of the IRA in regulating drug prices and the resulting implications for Medicare&apos;s budget. Additionally, it examines disparities in health care access and system preparedness for these new treatments. &lt;b&gt;CONCLUSIONS&lt;/b&gt;: The study findings underscore the need for a comprehensive approach to ensure fair pricing and equitable access to Alzheimer disease treatments. It suggests the application of frameworks such as the ISPOR Value Flower, focusing on diversity, equity, and comprehensive economic evaluations, to navigate the evolving landscape of Alzheimer disease treatment in the context of the IRA.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Li, Niying Rawal, Smita Young, Henry N Villa Zapata, Lorenzo</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.37765/ajmc.2024.89563</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9096</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9096</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mastroleo, Ignacio</style></author><author><style face="normal" font="default" size="100%">Daly, Timothy</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Avoiding Exceptionalism and Silver Bullets: Lessons from Public Health Ethics and Alzheimer&apos;s Disease</style></title><secondary-title><style face="normal" font="default" size="100%">The American Journal of Bioethics. Dec</style></secondary-title><short-title><style face="normal" font="default" size="100%">Avoiding Exceptionalism and Silver Bullets: Lessons from Public Health Ethics and Alzheimer&apos;s Disease</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">The American Journal of Bioethics. Dec</style></full-title></periodical><pages><style face="normal" font="default" size="100%">25-28</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer&apos;s disease</style></keyword><keyword><style face="normal" font="default" size="100%">Bioethics</style></keyword><keyword><style face="normal" font="default" size="100%">Emergency use authorization</style></keyword><keyword><style face="normal" font="default" size="100%">Ethics</style></keyword><keyword><style face="normal" font="default" size="100%">Exceptionalism</style></keyword><keyword><style face="normal" font="default" size="100%">Human rights</style></keyword><keyword><style face="normal" font="default" size="100%">Public health</style></keyword><keyword><style face="normal" font="default" size="100%">Research ethics</style></keyword><keyword><style face="normal" font="default" size="100%">Universalism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">1526-5161</style></isbn><abstract><style face="normal" font="default" size="100%">Lynch&apos;s et al.&apos;s (2021) work &quot;Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-pandemic Diseases?&quot; (Lynch et al. 2021) is an essential contribution by a leading working group in the field of ethics and regulation of unproven biomedical interventions.We agree that the response to the COVID-19 pandemic should motivate changes to the social institutions and regulations of health-care and research for other public health problems. Advocacy should focus less on silver bullets--Operation Warp Speed (OWS) levels of funding for developing biomedical interventions and Emergency Use Authorization (EUA) standards of access to unproven interventions outside trials and more, as the authors state, on improving collaboration, research (prioritization, design, and data sharing), and availability of clinical trials and monitored unproven interventions (i.e., Expanded Access pathway). We also believe that desperate patients and families with severe diseases or conditions deserve an ethical justification for restricting their claims of OWS funding and EUA access.Lynch et al. prove two arguments to do this: significant difference and harm to others. The &quot;significant differences&quot; argument only works from an ethical exceptionalist point of view. However, this point of view should be replaced with ethical universalism. The main ethical argument for restricting EUA and OWS is then its potential harm to others.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Using Smart Source Parsing</style></notes><work-type><style face="normal" font="default" size="100%">Journal Article</style></work-type><urls></urls><remote-database-name><style face="normal" font="default" size="100%">PHIL</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9116</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Padala, S. P.</style></author><author><style face="normal" font="default" size="100%">Yarns, B. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Padala, Sanjana P. Vanderbilt University, College of Arts and Sciences/Medicine, Health and Society, Nashville, TN, USA. Yarns, Brandon C. Department of Psychiatry/Mental Health, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA. Yarns, Brandon C. Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Under-Represented Populations Left Out of Alzheimer&apos;s Disease Treatment with Aducanumab: Commentary on Ethics</style></title><secondary-title><style face="normal" font="default" size="100%">JAD Reports</style></secondary-title><alt-title><style face="normal" font="default" size="100%">JAD Rep</style></alt-title><short-title><style face="normal" font="default" size="100%">Under-Represented Populations Left Out of Alzheimer&apos;s Disease Treatment with Aducanumab: Commentary on Ethics</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAD Reports</style></full-title><abbr-1><style face="normal" font="default" size="100%">JAD Rep</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">JAD Reports</style></full-title><abbr-1><style face="normal" font="default" size="100%">JAD Rep</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">345-348</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">2542-4823</style></isbn><accession-num><style face="normal" font="default" size="100%">35891635</style></accession-num><abstract><style face="normal" font="default" size="100%">Despite controversy about the efficacy and safety of aducanumab, the FDA&apos;s fast-tracking of this medicine is truly historic. However, structural problems leading to socioeconomic disparities and systemic racism in science, healthcare, and society have left out under-represented populations. This perspective outlines the racial and socioeconomic health disparities in aducanumab treatment: 1) Disparities in the risk of Alzheimer&apos;s disease (AD), 2) Limited participation from under-represented groups in AD trials raising concerns about the generalizability of the results, 3) Questionable applicability of the amyloid hypothesis in groups under-represented in AD research, and 4) Aducanumab&apos;s initial sticker price that unfairly singled out those with lower socioeconomic backgrounds. Potential solutions are discussed.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Padala, Sanjana P Yarns, Brandon C IK2 CX001884</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.3233/ADR-220023</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9105</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9105</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Post, S. G.</style></author><author><style face="normal" font="default" size="100%">Beerman, B.</style></author><author><style face="normal" font="default" size="100%">Brodaty, H.</style></author><author><style face="normal" font="default" size="100%">Gaines, A. W.</style></author><author><style face="normal" font="default" size="100%">Gauthier, S. G.</style></author><author><style face="normal" font="default" size="100%">Geldmacher, D. S.</style></author><author><style face="normal" font="default" size="100%">Hill, S.</style></author><author><style face="normal" font="default" size="100%">Homma, A.</style></author><author><style face="normal" font="default" size="100%">Rossor, M. N.</style></author><author><style face="normal" font="default" size="100%">Whitehouse, P. J.</style></author><author><style face="normal" font="default" size="100%">Winblad, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Post, S G. Center for Biomedical Ethics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ethical issues in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines</style></title><secondary-title><style face="normal" font="default" size="100%">Alzheimer Disease &amp; Associated Disorders</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Alzheimer Dis Assoc Disord</style></alt-title><short-title><style face="normal" font="default" size="100%">Ethical issues in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Alzheimer Disease and Associated Disorders</style></full-title><abbr-1><style face="normal" font="default" size="100%">Alzheimer Dis. Assoc. Disord.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Alzheimer Dis Assoc Disord</style></abbr-2><abbr-3><style face="normal" font="default" size="100%">Alzheimer Disease &amp; Associated Disorders</style></abbr-3></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Alzheimer Disease and Associated Disorders</style></full-title><abbr-1><style face="normal" font="default" size="100%">Alzheimer Dis. Assoc. Disord.</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Alzheimer Dis Assoc Disord</style></abbr-2><abbr-3><style face="normal" font="default" size="100%">Alzheimer Disease &amp; Associated Disorders</style></abbr-3></alt-periodical><pages><style face="normal" font="default" size="100%">26-8</style></pages><volume><style face="normal" font="default" size="100%">11 Suppl 3</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">*Cross-Cultural Comparison</style></keyword><keyword><style face="normal" font="default" size="100%">*Dementia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Compounding</style></keyword><keyword><style face="normal" font="default" size="100%">*Ethics, Pharmacy</style></keyword><keyword><style face="normal" font="default" size="100%">Geriatric Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nootropic Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">*Nootropic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">0 (Nootropic Agents)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1997</style></year></dates><isbn><style face="normal" font="default" size="100%">0893-0341</style></isbn><accession-num><style face="normal" font="default" size="100%">9305511</style></accession-num><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Post, S G Beerman, B Brodaty, H Gaines, A W Gauthier, S G Geldmacher, D S Hill, S Homma, A Rossor, M N Whitehouse, P J Winblad, B</style></notes><urls></urls><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9100</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9100</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Raman, R.</style></author><author><style face="normal" font="default" size="100%">Quiroz, Y. T.</style></author><author><style face="normal" font="default" size="100%">Langford, O.</style></author><author><style face="normal" font="default" size="100%">Choi, J.</style></author><author><style face="normal" font="default" size="100%">Ritchie, M.</style></author><author><style face="normal" font="default" size="100%">Baumgartner, M.</style></author><author><style face="normal" font="default" size="100%">Rentz, D.</style></author><author><style face="normal" font="default" size="100%">Aggarwal, N. T.</style></author><author><style face="normal" font="default" size="100%">Aisen, P.</style></author><author><style face="normal" font="default" size="100%">Sperling, R.</style></author><author><style face="normal" font="default" size="100%">Grill, J. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Raman, Rema. Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego. Quiroz, Yakeel T. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Quiroz, Yakeel T. Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Langford, Oliver. Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego. Choi, Jiyoon. Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego. Ritchie, Marina. Institute for Memory Impairments and Neurological Disorders, University of California Irvine. Baumgartner, Morgan. Institute for Memory Impairments and Neurological Disorders, University of California Irvine. Rentz, Dorene. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Rentz, Dorene. Department of Neurology, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts. Aggarwal, Neelum T. Department of Neurological Sciences, Rush Alzheimer&apos;s Disease Center, Rush University, Chicago, Illinois. Aisen, Paul. Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego. Sperling, Reisa. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Sperling, Reisa. Department of Neurology, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts. Grill, Joshua D. Institute for Memory Impairments and Neurological Disorders, University of California Irvine. Grill, Joshua D. Department of Psychiatry and Human Behavior, University of California Irvine. Grill, Joshua D. Department of Neurobiology and Behavior, University of California Irvine.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA Network Open</style></secondary-title><alt-title><style face="normal" font="default" size="100%">JAMA netw</style></alt-title><short-title><style face="normal" font="default" size="100%">Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA Network Open</style></full-title><abbr-1><style face="normal" font="default" size="100%">JAMA netw</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">JAMA Network Open</style></full-title><abbr-1><style face="normal" font="default" size="100%">JAMA netw</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">e2114364</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/eh [Ethnology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Ethnicity/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient Selection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">07 01</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2574-3805</style></isbn><accession-num><style face="normal" font="default" size="100%">34228129</style></accession-num><abstract><style face="normal" font="default" size="100%">&lt;b&gt;Importance&lt;/b&gt;: Underrepresentation of many racial/ethnic groups in Alzheimer disease (AD) clinical trials limits generalizability of results and hinders opportunities to examine potential effect modification of candidate treatments. &lt;b&gt;Objective&lt;/b&gt;: To examine racial and ethnic differences in recruitment methods and trial eligibility in a multisite preclinical AD trial. &lt;b&gt;Design, Setting, and Participants&lt;/b&gt;: This cross-sectional study analyzed screening data from the Anti-Amyloid in Asymptomatic AD study, collected from April 2014 to December 2017. Participants were categorized into 5 mutually exclusive ethnic/racial groups (ie, Hispanic, Black, White, Asian, and other) using participant self-report. Data were analyzed from May through December 2020 and included 5945 cognitively unimpaired older adults between the ages of 65 and 85 years screened at North American study sites. &lt;b&gt;Main Outcomes and Measures&lt;/b&gt;: Primary outcomes included recruitment sources, study eligibility, and ineligibility reasons. To assess the probability of trial eligibility, regression analyses were performed for the likelihood of being eligible after the first screening visit involving clinical and cognitive assessments. &lt;b&gt;Results&lt;/b&gt;: Screening data were included for 5945 participants at North American sites (mean [SD] age, 71.7 [4.9] years; 3524 women [59.3%]; 5107 White [85.9%], 323 Black [5.4%], 261 Hispanic [4.4%], 112 Asian [1.9%], and 142 [2.4%] who reported race or ethnicity as other). Recruitment sources differed by race and ethnicity. While White participants were recruited through a variety of sources, site local recruitment efforts resulted in the majority of Black (218 [69.2%]), Hispanic (154 [59.7%]), and Asian (61 [55.5%]) participants. Participants from underrepresented groups had lower mean years of education (eg, mean [SD] years: Hispanic participants, 15.5 [3.2] years vs White participants, 16.7 [2.8] years) and more frequently were women (226 [70.0%] Black participants vs 1364 [58.5%] White participants), were unmarried (184 [56.9%] Black participants vs 1364 [26.7%] White participants), and had nonspousal study partners (237 [73.4%] Black participants vs 2147 [42.0%] White participants). They were more frequently excluded for failure to meet cognitive inclusion criteria (eg, screen failures by specific inclusion criteria: 147 [45.5%] Black participants vs 1338 [26.2%] White participants). Compared with White participants, Black (odds ratio [OR], 0.43; 95% CI, 0.34-0.54; P &lt; .001), Hispanic (OR, 0.53; 95% CI, 0.41-0.69; P &lt; .001), and Asian participants (OR, 0.56; 95% CI, 0.38-0.82; P = .003) were less likely to be eligible after screening visit 1. &lt;b&gt;Conclusions and Relevance&lt;/b&gt;: Racial/ethnic groups differed in sources of recruitment, reasons for screen failure, and overall probability of eligibility in a preclinical AD trial. These results highlight the need for improved recruitment strategies and careful consideration of eligibility criteria when planning preclinical AD clinical trials.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Raman, Rema Quiroz, Yakeel T Langford, Oliver Choi, Jiyoon Ritchie, Marina Baumgartner, Morgan Rentz, Dorene Aggarwal, Neelum T Aisen, Paul Sperling, Reisa Grill, Joshua D Comment in (CIN) K24 AG035007 R01 AG063689 U19 AG010483 UL1 TR001414</style></notes><work-type><style face="normal" font="default" size="100%">Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov&apos;t</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1001/jamanetworkopen.2021.14364</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9093</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9093</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reardon, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Alzheimer&apos;s drug trials plagued by lack of racial diversity</style></title><secondary-title><style face="normal" font="default" size="100%">Nature</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nature</style></alt-title><short-title><style face="normal" font="default" size="100%">Alzheimer&apos;s drug trials plagued by lack of racial diversity</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nature</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nature</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Nature</style></abbr-2></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Nature</style></full-title><abbr-1><style face="normal" font="default" size="100%">Nature</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">Nature</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">256-257</style></pages><volume><style face="normal" font="default" size="100%">620</style></volume><number><style face="normal" font="default" size="100%">7973</style></number><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/mt [Methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/st [Standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default" size="100%">*Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Healthcare Disparities/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default" size="100%">*Healthcare Disparities</style></keyword><keyword><style face="normal" font="default" size="100%">Minority Groups/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default" size="100%">*Minority Groups</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Safety/st [Standards]</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Racial Groups/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default" size="100%">*Racial Groups</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Uncertainty</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1476-4687</style></isbn><accession-num><style face="normal" font="default" size="100%">37532857</style></accession-num><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Reardon, Sara</style></notes><work-type><style face="normal" font="default" size="100%">News</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1038/d41586-023-02464-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9095</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9095</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Smith, A. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Smith, A David. Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-amyloid trials raise scientific and ethical questions</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Bmj</style></alt-title><short-title><style face="normal" font="default" size="100%">Anti-amyloid trials raise scientific and ethical questions</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMJ</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">BMJ</style></abbr-2></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">BMJ</style></full-title><abbr-1><style face="normal" font="default" size="100%">BMJ</style></abbr-1><abbr-2><style face="normal" font="default" size="100%">BMJ</style></abbr-2></alt-periodical><pages><style face="normal" font="default" size="100%">n805</style></pages><volume><style face="normal" font="default" size="100%">372</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Cognition</style></keyword><keyword><style face="normal" font="default" size="100%">*Ethics Committees, Research</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Informed Consent</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">03 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1756-1833</style></isbn><accession-num><style face="normal" font="default" size="100%">33771816</style></accession-num><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Smith, A David Comment on (CON)</style></notes><work-type><style face="normal" font="default" size="100%">Letter Comment</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1136/bmj.n805</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9102</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9102</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van Veluw, S. J.</style></author><author><style face="normal" font="default" size="100%">Young, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">van Veluw, Susanne J. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Young, Michael J. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ethical considerations for the use of anti-amyloid immunotherapy in patients with early Alzheimer&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">Alzheimer&apos;s &amp; Dementia</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Alzheimer&apos;s dement</style></alt-title><short-title><style face="normal" font="default" size="100%">Ethical considerations for the use of anti-amyloid immunotherapy in patients with early Alzheimer&apos;s disease</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Alzheimer&apos;s &amp; Dementia</style></full-title><abbr-1><style face="normal" font="default" size="100%">Alzheimer&apos;s dement</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Alzheimer&apos;s &amp; Dementia</style></full-title><abbr-1><style face="normal" font="default" size="100%">Alzheimer&apos;s dement</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">3664-3665</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/th [Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloid beta-Peptides</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">05</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1552-5279</style></isbn><accession-num><style face="normal" font="default" size="100%">38528327</style></accession-num><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">van Veluw, Susanne J Young, Michael J</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1002/alz.13795</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Dump-Converted.enl" path="C:\Users\MelissaW\OneDrive - CADTH\Desktop\Dump-Converted.enl">Dump-Converted.enl</database><source-app name="EndNote" version="21.3">EndNote</source-app><rec-number>9115</rec-number><foreign-keys><key app="EN" db-id="r2sx9vrrj0wfxmezzz15sraze29x5ttrxp00">9115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yeo-Teh, N. S. L.</style></author><author><style face="normal" font="default" size="100%">Tang, B. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Yeo-Teh, Nicole Shu Ling. Research Compliance and Integrity Office, National University of Singapore, Singapore, Singapore. dprysln@nus.edu.sg. Tang, Bor Luen. Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. bchtbl@nus.edu.sg.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer&apos;s Disease</style></title><secondary-title><style face="normal" font="default" size="100%">Science &amp; Engineering Ethics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Sci Eng Ethics</style></alt-title><short-title><style face="normal" font="default" size="100%">A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer&apos;s Disease</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Science &amp; Engineering Ethics</style></full-title><abbr-1><style face="normal" font="default" size="100%">Sci Eng Ethics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Science &amp; Engineering Ethics</style></full-title><abbr-1><style face="normal" font="default" size="100%">Sci Eng Ethics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">2</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/co [Complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">01 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-5546</style></isbn><accession-num><style face="normal" font="default" size="100%">36625928</style></accession-num><abstract><style face="normal" font="default" size="100%">Alzheimer&apos;s disease (AD), the devastating and most prevailing underlying cause for age-associated dementia, has no effective disease-modifying treatment. The last approved drug for the relief of AD symptoms was in 2003. The recent approval of sodium oligomannate (GV-971, 2019) in China and the human antibody aducanumab in the USA (ADUHELM, 2021) therefore represent significant breakthroughs, albeit ones that are fraught with controversy. Here, we explore potential scientific ethics issues associated with GV-971 and aducanumab&apos;s development and approval. While these issues may be belied by socioeconomic and political complexities in the heady business of commercial drug development, they are of fundamental importance to scientific integrity and ultimately, welfare of patients. We posit that the push for approval of both AD drugs based on incomplete research and unconvincing marginal effectiveness is ethically unsound. Regardless of how both these drugs shall perform in the market for the years to come, the scientific ethics issues and potentially questionable research practices should therefore be duly noted and lessons learned.</style></abstract><label><style face="normal" font="default" size="100%">Anti-Amyloid</style></label><notes><style face="normal" font="default" size="100%">Yeo-Teh, Nicole Shu Ling Tang, Bor Luen</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://dx.doi.org/10.1007/s11948-022-00422-0</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">Ovid Technologies</style></remote-database-provider><language><style face="normal" font="default" size="100%">English</style></language></record></records></xml>